Neither measured nor predicted prosthesis-patient mismatch (PPM) predicted 5-year mortality in valve-in-valve TAVI patients, with 5-year mortality ~52%.
Does severe measured or predicted prosthesis-patient mismatch increase 5-year mortality in patients undergoing valve-in-valve TAVI?
Neither measured nor predicted severe prosthesis-patient mismatch was predictive of 5-year mortality in patients undergoing valve-in-valve TAVI.
Absolute Event Rate: 0% vs 0%
ABSTRACT Background This study's objective was to investigate the incidence and long‐term outcomes of measured (PPM M ) and predicted (PPM P ) prosthesis‐patient mismatch in patients undergoing valve‐in‐valve (ViV) transcatheter aortic valve implantation (TAVI). Aims To assess the outcomes of predicted and measured PPM in patients undergoing ViV TAVI. Methods This retrospective, multicenter analysis included patients who underwent ViV TAVI at the Baylor Scott 84.0] years. The median STS risk score was 6.3 3.5; 9.65 %. TAVI was performed trans‐femorally in 95.7%, using balloon‐expandable (52.5%) and self‐expanding (47.5%) devices. The incidence of severe PPMP was significantly lower than that of severe PPMM, both before (14.8% vs. 28.4%, p = 0.005) and after adjusting for BMI (11.1% vs. 24.7%, p = 0.002). Both severe PPMP and PPMM predicted high residual pressure gradient (≥ 20mmHg) ( p = 0.004, p = 0.002, respectively), with no statistical superiority (Delong test, p = 0.82). Five‐year mortality was 52% for PPMM and 51% for PPMP. Severe‐PPMM and severe‐PPMP were not significantly associated to increased mortality when compared to the absence of PPMM (50% vs. 57% survival; HR 1.76, p = 0.221) or PPMP (69% vs. 58% survival; HR 0.81, p = 0.713), respectively. Conclusions In this single healthcare system experience, neither measured PPM nor predicted PPM were predictive of 5‐year mortality in patients undergoing ViV‐TAVI.
Al-Azizi et al. (Sun,) reported a other. Neither measured nor predicted prosthesis-patient mismatch (PPM) predicted 5-year mortality in valve-in-valve TAVI patients, with 5-year mortality ~52%.